Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this randomized control trial, researchers reported that topical calcipotriol was more effective than topical tacrolimus in promoting hair growth for patients with alopecia areata over a 6-month period, with a statistically significant difference in efficacy.

This randomized controlled trial found that vitamin D supplementation significantly improved various post-COVID-19 symptoms, such as fatigue and sleep disturbances, compared to placebo over two months, emphasizing the role of vitamin D deficiency in persistent symptoms among post-COVID-19 patients.

This clinical trial found that combining fractional CO2 laser with bimatoprost solution significantly improved alopecia areata treatment outcomes compared to bimatoprost alone, as measured by a more substantial reduction in SALT scores and higher patient satisfaction over 12 weeks.

In this randomized controlled trial, combining 4-weekly microneedling with 5% minoxidil significantly increased hair density and diameter in men with androgenetic alopecia compared to minoxidil alone, while side effects were minor and tolerable.

In this study, researchers found that platelet-rich plasma therapy demonstrated significantly higher efficacy than topical minoxidil for treating androgenetic alopecia in a Pakistani population, with a 91.7% negative hair pull rate compared to 69.4% for minoxidil after 12 weeks.

CTP-543 is generally safe for treating alopecia areata.

This study found that while both topical cetirizine and minoxidil improved female pattern hair loss, minoxidil was significantly more effective in increasing hair density.

In this randomized controlled trial, researchers found that Cellcurin therapy significantly increased hair density, terminal hair, and vellus hair counts in men and women with androgenetic alopecia, compared to minoxidil control, over 12 weeks.

In this study, autologous hair follicle mesenchymal stem cell therapy was effective in promoting hair growth in Chinese patients with advanced androgenic alopecia, particularly improving hair shaft diameter in follicles less than 60 µm without obvious side effects.

In this randomized controlled trial, researchers found that participants with androgenic alopecia taking an Annurca apple extract supplement showed significant increases in hair density and weight and reduced hair loss compared to a placebo, with good skin and gastrointestinal tolerability over 180 days.

This prospective randomized controlled trial found that combining platelet-rich plasma plus basic fibroblast growth factor injections with topical minoxidil significantly improves hair count and growth rate in androgenetic alopecia patients compared to either treatment alone.

In this study, intralesional triamcinolone acetonide 10 mg/mL combined with topical betamethasone dipropionate 0.05% lotion was found to be more effective for treating alopecia areata than either treatment alone.

In this randomized controlled trial, the nutritional supplement PPT5 α was associated with increased terminal hair percentages and improved self-assessed hair parameters in women with early-stage androgenetic alopecia.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

This study found that a new propylene glycol-free 5% minoxidil lotion demonstrated good clinical efficacy and very good cosmetic acceptability and tolerability after six months of use in patients with androgenetic alopecia, showing results comparable to traditional formulations containing propylene glycol.

This study found that oral contraceptives containing cyproterone acetate improved the overall quality of life in PCOS patients more than those containing levonorgestrel after 6 months of treatment.

In this randomized controlled clinical study, researchers found that Neem and Zanjabeel treatment was as effective as standard hormonal therapy in reducing hirsutism and improving biochemical and hormonal parameters in women with polycystic ovarian disease, while also significantly lowering fasting insulin and lipid levels.

This study found that topical applications of bergamot oil at 2.5% and 5% concentrations were more effective in treating Dermatophytosis in cattle and cats, leading to faster recovery compared to a 1.25% concentration.

In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.

This abstract reviews testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production and reports no new research findings.

Acne treatment, including isotretinoin, improves quality of life and does not worsen depression.

This study suggests that oral zinc sulphate may be an effective and safe treatment for thallium poisoning, particularly in improving dermatological symptoms and reducing the progression of the condition.

In this randomized study, patients with early favorable Hodgkin lymphoma showed similar complete remission and survival rates whether receiving 2 or 4 cycles of ABVD and 20 Gy or 30 Gy IFRT, though reduced toxicity was associated with fewer cycles and lower radiation doses.

This study found that patients with alopecia areata showed significant improvement with topical minoxidil, intralesional steroids, and cryotherapy compared to placebo, without interfering side effects.

This abstract reports preliminary data on the antidepressant reboxetine, noted for its different mode of action, discussed at a major psychiatry conference; it provides no new research findings.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.

In this study, researchers examined a new propylene glycol-free 5% minoxidil lotion for 6 months among individuals with androgenic alopecia and found it demonstrated good clinical efficacy, with 74% showing a positive response, and very high cosmetic acceptability and tolerability, comparable to traditional formulations.